152 related articles for article (PubMed ID: 31039251)
1. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.
Ruth MM; Magombedze G; Gumbo T; Bendet P; Sangen JJN; Zweijpfenning S; Hoefsloot W; Pennings L; Koeken VACM; Wertheim HFL; Lee PS; van Ingen J; Deshpande D
J Antimicrob Chemother; 2019 Jul; 74(7):1952-1961. PubMed ID: 31039251
[TBL] [Abstract][Full Text] [Related]
2. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i30-i35. PubMed ID: 28922807
[TBL] [Abstract][Full Text] [Related]
3. Linezolid as treatment for pulmonary Mycobacterium avium disease.
Deshpande D; Srivastava S; Pasipanodya JG; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i24-i29. PubMed ID: 28922806
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
Deshpande D; Srivastava S; Meek C; Leff R; Hall GS; Gumbo T
Antimicrob Agents Chemother; 2010 Jun; 54(6):2534-9. PubMed ID: 20385862
[TBL] [Abstract][Full Text] [Related]
5. Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far.
Singh S; Boorgula GD; Aryal S; Philley JV; Gumbo T; Srivastava S
J Antimicrob Chemother; 2024 Jan; 79(1):96-99. PubMed ID: 37946564
[TBL] [Abstract][Full Text] [Related]
6. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i48-i53. PubMed ID: 28922809
[TBL] [Abstract][Full Text] [Related]
7. Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses.
Chapagain M; Pasipanodya JG; Athale S; Bernal C; Trammell R; Howe D; Gumbo T
J Antimicrob Chemother; 2022 May; 77(6):1694-1705. PubMed ID: 35257162
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
van Ingen J; Egelund EF; Levin A; Totten SE; Boeree MJ; Mouton JW; Aarnoutse RE; Heifets LB; Peloquin CA; Daley CL
Am J Respir Crit Care Med; 2012 Sep; 186(6):559-65. PubMed ID: 22744719
[TBL] [Abstract][Full Text] [Related]
9. A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease.
Srivastava S; Deshpande D; Sherman CM; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i43-i47. PubMed ID: 28922810
[TBL] [Abstract][Full Text] [Related]
10. Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance.
Srivastava S; Deshpande D; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i20-i23. PubMed ID: 28922805
[TBL] [Abstract][Full Text] [Related]
11. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.
Deshpande D; Srivastava S; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2010 May; 54(5):1728-33. PubMed ID: 20231389
[TBL] [Abstract][Full Text] [Related]
12. Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.
Deshpande D; Srivastava S; Musuka S; Gumbo T
Antimicrob Agents Chemother; 2016 Aug; 60(8):4652-8. PubMed ID: 27216055
[TBL] [Abstract][Full Text] [Related]
13. A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.
Deshpande D; Srivastava S; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i54-i60. PubMed ID: 28922811
[TBL] [Abstract][Full Text] [Related]
14. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease.
Deshpande D; Pasipanodya JG; Gumbo T
Antimicrob Agents Chemother; 2016 Apr; 60(4):2157-63. PubMed ID: 26810646
[TBL] [Abstract][Full Text] [Related]
15. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
16. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
Yamaba Y; Ito Y; Suzuki K; Kikuchi T; Ogawa K; Fujiuchi S; Hasegawa N; Kurashima A; Higuchi T; Uchiya KI; Watanabe A; Niimi A
J Infect Chemother; 2019 Dec; 25(12):995-1000. PubMed ID: 31239192
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium.
Deshpande D; Gumbo T
Future Microbiol; 2011 Apr; 6(4):433-9. PubMed ID: 21526944
[TBL] [Abstract][Full Text] [Related]
19. The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.
Deshpande D; Srivastava S; Chapagain ML; Lee PS; Cirrincione KN; Pasipanodya JG; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i36-i42. PubMed ID: 28922808
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
Brown-Elliott BA; Iakhiaeva E; Griffith DE; Woods GL; Stout JE; Wolfe CR; Turenne CY; Wallace RJ
J Clin Microbiol; 2013 Oct; 51(10):3389-94. PubMed ID: 23946523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
